SuperworthBiogen Inc. BIIB
Drug Manufacturers - General, Healthcare
$222.15
−0.33%
- Market cap
- $32.8B
- PE
- 39.3×
- 10y median 16.1×
- Forward PE
- Price to sales
- 3.3×
- EV/EBIT
- 23.7×
- Revenue, 12 months
- $10B
- +0% on a year ago
- Net margin
- 8.3%
- Free cash flow yield
- 8.2%
Biogen trades at 39.3× trailing earnings, pricier than 99% of the last ten years. Revenue was $10B over the last twelve months, up 0% on a year earlier with a 8% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.4B | $2.3B | $2.5B | $2.5B | $2.5B+3% | $2.4B+6% | $2.6B+7% | $2.5B+3% | $2.3B−7% | $2.5B+2% | $2.7B+3% | |
| Cost of revenue | $618.3M | $542.2M | $546M | $638.7M | $583.5M−6% | $629.3M+16% | $605M+11% | $674.4M+6% | $495.5M−15% | $661M+5% | $776.9M+28% |
| Gross profit | $1.8B | $1.7B | $1.9B | $1.8B | $1.9B+6% | $1.8B+3% | $2B+6% | $1.9B+2% | $1.8B−5% | $1.8B+1% | $2B−4% |
| R&D | $554.3M | $445.4M | $505.4M | $516.2M | $513.3M−7% | $434.1M−3% | $399M−21% | $436.1M−16% | $509.4M−1% | $539M+24% | $529.6M+33% |
| SG&A | $608.5M | $581.5M | $553.8M | $588.4M | $680M+12% | $572.5M−2% | $583.8M+5% | $594.8M+1% | $682.5M+0% | $607.3M+6% | $709.7M+22% |
| $512.4M | $690.4M | $366.5M | $577.2M | $509M−1% | $732.6M+6% | $588.1M+61% | $613.8M+6% | −$57M | $397.4M−46% | $318.1M−46% | |
| Interest expense | $71.5M | $69.2M | $61.3M | $59.8M | $60M−16% | $60M−13% | $72.6M+18% | $67.4M+13% | $67.5M+13% | $67.6M+13% | $82.3M+13% |
| Pre-tax income | $291.6M | $464.8M | $698.7M | $451M | $291.5M+0% | $311.2M−33% | $744M+7% | $557.3M+24% | −$56M | $377.7M+21% | $132.4M−82% |
| $42.7M | $71.4M | $115.1M | $62.5M | $24.8M−42% | $70.7M−1% | $109.2M−5% | $90.8M+45% | −$7.1M | $58.2M−18% | $34.9M−68% | |
| Net income | $249.7M | $393.4M | $583.6M | $388.5M | $266.7M+7% | $240.5M−39% | $634.8M+9% | $466.5M+20% | −$48.9M | $319.5M+33% | $97.5M−85% |
| $1.71 | $2.70 | $4.00 | $2.66 | $1.83+7% | $1.64−39% | $4.33+8% | $3.17+19% | −$0.33 | $2.15+31% | $0.66−85% | |
| 145.7M | 145.9M | 145.9M | 146.1M | 146.1M+0% | 146.6M+1% | 146.7M+1% | 147.1M+1% | 146.7M+0% | 148.4M+1% | 148.7M+1% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Drug Manufacturers - General within ten times Biogen's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BIIBBiogen Inc. | $32.8B | 39.3× | 16.1× | 3.3× | +0% | 8.3% | |
| BMYBristol-Myers Squibb Company | $122B | 13.1× | 19.9× | 2.5× | +3% | 18.9% | |
| PFEPfizer Inc. | $159.6B | 36.8× | 16.3× | 2.5× | −0% | 6.8% | |
| AMGNAmgen Inc. | $223.3B | 25.7× | 21.0× | 5.9× | +9% | 23.0% | |
| Peer median | $159.6B | 25.7× | 19.9× | 2.5× | +3% | 18.9% |
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .